126 related articles for article (PubMed ID: 24814045)
1. BRCA2 gene: a candidate for clinical testing in familial colorectal cancer type X.
Garre P; Martín L; Sanz J; Romero A; Tosar A; Bando I; Llovet P; Diaque P; García-Paredes B; Díaz-Rubio E; de la Hoya M; Caldés T
Clin Genet; 2015 Jun; 87(6):582-7. PubMed ID: 24814045
[TBL] [Abstract][Full Text] [Related]
2. Analysis of somatic molecular changes, clinicopathological features, family history, and germline mutations in colorectal cancer families: evidence for efficient diagnosis of HNPCC and for the existence of distinct groups of non-HNPCC families.
Johnson V; Lipton LR; Cummings C; Eftekhar Sadat AT; Izatt L; Hodgson SV; Talbot IC; Thomas HJ; Silver AJ; Tomlinson IP
J Med Genet; 2005 Oct; 42(10):756-62. PubMed ID: 15788729
[TBL] [Abstract][Full Text] [Related]
3. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
4. Role of MYH polymorphisms in sporadic colorectal cancer in China: a case-control, population-based study.
Yang L; Huang XE; Xu L; Zhou JN; Yu DS; Zhou X; Li DZ; Guan X
Asian Pac J Cancer Prev; 2013; 14(11):6403-9. PubMed ID: 24377541
[TBL] [Abstract][Full Text] [Related]
5. GALNT12 is not a major contributor of familial colorectal cancer type X.
Seguí N; Pineda M; Navarro M; Lázaro C; Brunet J; Infante M; Durán M; Soto JL; Blanco I; Capellá G; Valle L
Hum Mutat; 2014 Jan; 35(1):50-2. PubMed ID: 24115450
[TBL] [Abstract][Full Text] [Related]
6. Inherited BRCA1 and RNF43 pathogenic variants in a familial colorectal cancer type X family.
Chan JM; Clendenning M; Joseland S; Georgeson P; Mahmood K; Joo JE; Walker R; Como J; Preston S; Chai SM; Chu YL; Meyers AL; Pope BJ; Duggan D; Fink JL; Macrae FA; Rosty C; Winship IM; Jenkins MA; Buchanan DD
Fam Cancer; 2024 Mar; 23(1):9-21. PubMed ID: 38063999
[TBL] [Abstract][Full Text] [Related]
7. cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation.
Zhang L; Bacares R; Boyar S; Hudis C; Nafa K; Offit K
Mutat Res; 2009 Apr; 663(1-2):84-9. PubMed ID: 19070627
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer.
Agalliu I; Kwon EM; Zadory D; McIntosh L; Thompson J; Stanford JL; Ostrander EA
Clin Cancer Res; 2007 Feb; 13(3):839-43. PubMed ID: 17289875
[TBL] [Abstract][Full Text] [Related]
10. Mass spectrometry-based loss of heterozygosity analysis of single-nucleotide polymorphism loci in paraffin embedded tumors using the MassEXTEND assay: single-nucleotide polymorphism loss of heterozygosity analysis of the protein tyrosine phosphatase receptor type J in familial colorectal cancer.
van Puijenbroek M; Dierssen JW; Stanssens P; van Eijk R; Cleton-Jansen AM; van Wezel T; Morreau H
J Mol Diagn; 2005 Nov; 7(5):623-30. PubMed ID: 16258161
[TBL] [Abstract][Full Text] [Related]
11. BRCA2 mutations as a universal risk factor for pancreatic cancer has a limited role in Korean ethnic group.
Cho JH; Bang S; Park SW; Chung JB; Song SY
Pancreas; 2008 May; 36(4):337-40. PubMed ID: 18437078
[TBL] [Abstract][Full Text] [Related]
12. A novel missense germline mutation in exon 2 of the hMSH2 gene in a HNPCC family from Southern Italy.
Baudi F; Fersini G; Lavecchia A; Terracciano R; Leone F; Quaresima B; Faniello MC; De Paola L; Doldo P; Cuda G; Costanzo F; Venuta S
Cancer Lett; 2005 Jun; 223(2):285-91. PubMed ID: 15896463
[TBL] [Abstract][Full Text] [Related]
13. Pathogenicity evaluation of BRCA1 and BRCA2 unclassified variants identified in Portuguese breast/ovarian cancer families.
Santos C; Peixoto A; Rocha P; Pinto P; Bizarro S; Pinheiro M; Pinto C; Henrique R; Teixeira MR
J Mol Diagn; 2014 May; 16(3):324-34. PubMed ID: 24607278
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.
Surowy HM; Sutter C; Mittnacht M; Klaes R; Schaefer D; Evers C; Burgemeister AL; Goehringer C; Dikow N; Heil J; Golatta M; Schott S; Schneeweiss A; Bugert P; Sohn C; Bartram CR; Burwinkel B
Breast Cancer Res Treat; 2014 Jun; 145(2):451-60. PubMed ID: 24728577
[TBL] [Abstract][Full Text] [Related]
15. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
[TBL] [Abstract][Full Text] [Related]
16. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
[TBL] [Abstract][Full Text] [Related]
17. Somatic mutations and germline sequence variants in patients with familial colorectal cancer.
Gylfe AE; Sirkiä J; Ahlsten M; Järvinen H; Mecklin JP; Karhu A; Aaltonen LA
Int J Cancer; 2010 Dec; 127(12):2974-80. PubMed ID: 21351276
[TBL] [Abstract][Full Text] [Related]
18. PALB2 analysis in BRCA2-like families.
Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility genetic variants associated with early-onset colorectal cancer.
Giráldez MD; López-Dóriga A; Bujanda L; Abulí A; Bessa X; Fernández-Rozadilla C; Muñoz J; Cuatrecasas M; Jover R; Xicola RM; Llor X; Piqué JM; Carracedo A; Ruiz-Ponte C; Cosme A; Enríquez-Navascués JM; Moreno V; Andreu M; Castells A; Balaguer F; Castellví-Bel S;
Carcinogenesis; 2012 Mar; 33(3):613-9. PubMed ID: 22235025
[TBL] [Abstract][Full Text] [Related]
20. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
